Biotech News
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
ir.kuraoncology.com2026-05-06 14:56 EST
– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of